menu ☰
menu ˟

Atogepant well tolerated, effectively reduces migraine days

12 Jul 2019
PHILADELPHIA — Atogepant, a novel, oral calcitonin gene-related peptide receptor in development for the prevention of migraine, achieved positive results in trials presented at the American Headache Society Annual Meeting.Two studies evaluated data...

Click here to view the full article which appeared in Psychiatry

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.